Compare Amgen, Inc. (AMGN) vs Pinterest Inc (PINS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Pinterest Inc — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while Pinterest Inc trades at $22.63 (market cap $12.61B). The key difference: Amgen, Inc. is far larger — about 15.6× Pinterest Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Pinterest Inc pays none. Which is the better fit depends on your goals.
| AMGN | PINS | |
|---|---|---|
Market Cap | $196.12B | $12.61B |
Sector | Health | Media |
52-Week High | $388.16 | $39.17 |
52-Week Low | $271.18 | $15.42 |
Enterprise Value | $241.41B | $12.52B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Pinterest (PINS) trades at $22.53, down 0.71% on the day, with a bullish technical outlook supported by moving averages. The company reported revenue growth to $4.22B in 2025, with net income of $416.86M and a net margin of 9.87%. Recent news highlights AI-driven shopping initiatives and strong user growth, while analyst sentiment remains positive with a consensus price target of $27.72.
The stock presents a growth opportunity with improving profitability and strategic AI investments, but faces risks from competitive pressure and valuation concerns. Wall Street's bullish consensus suggests upside potential, though investors should monitor execution on monetization and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →
